Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Author(s): Hope S. Rugo, MD1; Aditya Bardia, MD, MPH2; Frederik Marmé, MD, PhD3; Javier Cortes, MD, PhD4,5; Peter Schmid, MD, PhD6; Delphine Loirat, MD, PhD7; Olivier Trédan, MD, PhD8; Eva Ciruelos, MD, PhD9; Florence Dalenc, MD, PhD10; Patricia Gómez Pardo, MD11; Komal L. Jhaveri, MD12; Rosemary Delaney, MPH13; Olivia Fu, MD14; Lanjia Lin, PhD15; Wendy Verret, PhD13; and Sara M. Tolaney, MD, MPH16
Source: DOI: 10.1200/JCO.22.01002 Journal of Clinical Oncology 40, no. 29 (October 10, 2022) 3365-3376
Dr. Maen Hussein's Thoughts
Another option for HR+ /HER-2 negative pts who failed hormonal therapies, caution to toxicity though esp neutropenia and diarrhea, no OS data yet, will be interesting to know if it worth the adverse events at this stage of disease.
ABSTRACT
PURPOSE
Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer.
METHODS
In this global, randomized, phase III study, SG was compared with physician’s choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2– locally recurrent inoperable or metastatic breast cancer. The primary end point was progression-free survival (PFS) by blinded independent central review.
RESULTS
Patients were randomly assigned to receive SG (n = 272) or chemotherapy (n = 271). The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease. Primary end point was met with a 34% reduction in risk of progression or death (hazard ratio, 0.66 [95% CI, 0.53 to 0.83; P = .0003]). The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively. Median overall survival (first planned interim analysis) was not yet mature (hazard ratio, 0.84; P = .14). Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).
CONCLUSION
SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2– advanced breast cancer and limited treatment options.
Author Affiliations
1Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 2Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 3Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Heidelberg, Germany; 4Medical Oncology Department, International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain; 5Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain; 6Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 7Medical Oncology Department and D3i, Institut Curie, Paris, France; 8Medical Oncology Department, Centre Léon Bérard, Lyon, France; 9Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; 10Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; 11Hospital Universitari Vall D’Hebron, Barcelona, Spain; 12Memorial Sloan-Kettering Cancer Center, New York, NY; 13Department of Clinical Development, Gilead Sciences Inc, Foster City, CA; 14Department of Global Patient Safety, Gilead Sciences Inc, Foster City, CA; 15Department of Biostatistics, Gilead Sciences Inc, Foster City, CA; 16Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MARelated Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
